The mammalian female reproductive tract, including the oviducts, uterus, and vagina, is essential for the continuation of the species and a frequent site of human disease, including infertility and cancer. The female reproductive tract is derived from the M?llerian ducts of the fetus, a pair of epithelial tubes with a surrounding mesenchyme. In mammals, two pairs of genital ducts form within the mesonephroi associated with the fetal gonads regardless of sex genotype. Initially, the Wolffian ducts form that subsequently give rise to the vas deferentia, epididymides, and seminal vesicles. The Wolffian ducts then guide the formation of the M?llerian ducts. In males, the fetal testes produce the TGF-b family member anti-M?llerian hormone (AMH) that binds receptors expressed in the M?llerian duct mesenchyme, causing the elimination of the M?llerian ducts. The fetal ovaries do not produce AMH, permitting M?llerian duct differentiation. Thus, mammalian fetuses are initially ambi-sexual with the potential to develop both male and female reproductive tract organs. Defects in the formation of the genital ducts and resolution of the ambi-sexual state to a male or female phenotype lead to disorders of sexual development (DSD). Although much progress has been made in understanding the development and differentiation of the female reproductive tract and the elimination of the M?llerian system in the male fetus there are still many fundamental unanswered questions. The primary objective of this proposal is to determine the molecular, cellular, and developmental mechanisms that regulate female reproductive tract organogenesis and its regression during male differentiation.
The mammalian female reproductive tract, including the oviducts, uterus, and vagina, is essential for the continuation of the species and an important site for human disease, notably infertility and cancer. Surprisingly, relatively little is known about the developmental genetics of female reproductive tract formation. The primary objective of this proposal is to determine the molecular, cellular, and developmental mechanisms that regulate female reproductive tract organogenesis and its regression during male differentiation.
|Gonzalez, Gabriel; Mehra, Shyamin; Wang, Ying et al. (2016) Sox9 overexpression in uterine epithelia induces endometrial gland hyperplasia. Differentiation 92:204-215|
|Huang, Cheng-Chiu; Orvis, Grant D; Kwan, Kin Ming et al. (2014) Lhx1 is required in MÃ¼llerian duct epithelium for uterine development. Dev Biol 389:124-36|
|Yen, Shuo-Ting; Zhang, Min; Deng, Jian Min et al. (2014) Somatic mosaicism and allele complexity induced by CRISPR/Cas9 RNA injections in mouse zygotes. Dev Biol 393:3-9|
|Nolte, Mark J; Wang, Ying; Deng, Jian Min et al. (2014) Functional analysis of limb transcriptional enhancers in the mouse. Evol Dev 16:207-23|
|Pawar, Sandeep; Starosvetsky, Elina; Orvis, Grant D et al. (2013) STAT3 regulates uterine epithelial remodeling and epithelial-stromal crosstalk during implantation. Mol Endocrinol 27:1996-2012|
|Laronda, Monica M; Unno, Kenji; Ishi, Kazutomo et al. (2013) Diethylstilbestrol induces vaginal adenosis by disrupting SMAD/RUNX1-mediated cell fate decision in the MÃ¼llerian duct epithelium. Dev Biol 381:5-16|
|Imuta, Yu; Kiyonari, Hiroshi; Jang, Chuan-Wei et al. (2013) Generation of knock-in mice that express nuclear enhanced green fluorescent protein and tamoxifen-inducible Cre recombinase in the notochord from Foxa2 and T loci. Genesis 51:210-8|
|Mazahery, Ahmad Reza; Suzuki, Kentaro; Nagafuchi, Akira et al. (2013) Functional analysis of ectodermal Î²-catenin during external genitalia formation. Congenit Anom (Kyoto) 53:34-41|
|Stewart, C Allison; Wang, Ying; Bonilla-Claudio, Margarita et al. (2013) CTNNB1 in mesenchyme regulates epithelial cell differentiation during MÃ¼llerian duct and postnatal uterine development. Mol Endocrinol 27:1442-54|
|Janovick, Jo Ann; Stewart, M David; Jacob, Darla et al. (2013) Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy. Proc Natl Acad Sci U S A 110:21030-5|
Showing the most recent 10 out of 104 publications